Accelerating Medicines Partnership Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2012
NCT01760005
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Accelerating Medicines Partnership (AMP)

Active Ingredients

Drugs in Phase 3 Trials (4)

e2814 (1 trial)

gantenerumab (2 trials)

LECANEMAB (Leqembi) (1 trial)

solanezumab (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Dementia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4